Scorpion venom peptides: what the research shows
Scorpion venom peptides are drawing fresh scientific attention for liver and inflammatory disease. Here is what preclinical studies have found so far.
Section
Research
New peer-reviewed peptide science, read at the source.
Looking for background? Browse the peptide research library — cited overviews of every compound, sorted by evidence tier.
-
-
LL‑37 Levels Reflect Sleep Quality in Obstructive Sleep Apnea
Observational study links plasma LL‑37 levels to sleep quality in obstructive sleep apnea, suggesting pLL‑37 as a potential biomarker of disease severity and immune vulnerability.
-
Systematic ranking of peptide drugs in new review
An updated systematic review grades peptide therapeutics across functional and evidence-based classes, offering comparative effectiveness insights in peptide drug science.
-
First‑in‑class non‑GLP‑1 peptide advances metabolic therapy
A first‑in‑class non‑GLP‑1 peptide—AT7687, a GIPR antagonist—has entered public awareness, marking a mechanistic departure within metabolic peptide therapeutics.
-
Scorpion Peptides: Antiviral Research Explained
A new review maps how scorpion peptides disrupt viral entry and replication across preclinical models. Here is what the antiviral research actually shows.
-
AmyP53 Nasal Spray: Nose-to-Brain Delivery Tested
A new study tested an AmyP53 nasal spray device for nose-to-brain delivery in Alzheimer's and Parkinson's disease models. Here's what the preclinical data show.
-
Case Report: Online‑Purchased Retatrutide Harms
Clinical case report describes complications after a patient self‑administered online‑purchased retatrutide, raising safety concerns over unregulated peptide use.
-
Calreticulin Mutations: A Peptide Immunotherapy Target
New research shows calreticulin mutations create a tumor-specific peptide target in blood cancers. Here's what the preclinical data reveal.
-
Bioactive Peptides: Gut Survival Explained
New research maps how bioactive peptides survive digestion, cross gut walls, and reach circulation — and why most never make it that far.
-
RGD Mimics and Fibrosis: New Preclinical Data
RGD mimics show anti-fibrotic effects in mice. Plus: nasal peptide delivery for brain injury and cancer peptide combos. Research digest.
-
Ghrelin Research: Alcohol's Hidden Peptide Effect
New preclinical ghrelin research reveals how alcohol disrupts glucose sensing and boosts ghrelin secretion. What in vitro findings mean for science.
-
GLP-1 Agonists and Opioid Use Disorder
New preclinical and early human data suggest GLP-1 agonists may reduce opioid cravings. Here's what the research actually shows.
-
Tesamorelin for HIV Lipodystrophy: New Data
A 2025 meta-analysis reviews tesamorelin efficacy and safety in HIV-associated lipodystrophy. Here's what the clinical evidence shows.
-
Antimicrobial Peptides: 2025 Breakthroughs
New antimicrobial peptides derived from myxinidin show high efficacy in preclinical bacterial pneumonia models. Here's what the 2025 research reveals.
-
Peptide Research: 6 Breakthroughs Decoded
New peptide research spans cancer therapy, wound healing, and pain relief. Explore 6 studies shaping the future of peptide science in 2025.
-
Antimicrobial Peptides Fight Pneumonia
New antimicrobial peptides derived from myxinidin show high efficacy against bacterial pneumonia in preclinical models. Here's what the research found.
-
Peptide Research: 8 Studies Decoded
Peptide research roundup: eight new studies explore cancer vaccines, desmopressin in osteosarcoma, beta-endorphin pain relief, and migraine therapy.
-
GHRP-6 and EGF: Easing Cognitive Decline
New preclinical research explores how GHRP-6 co-administration with EGF may attenuate cognitive decline. Here's what the early data show.
-
Antimicrobial Peptides Target Ear Fungi
Genomic analysis of otomycosis fungi is guiding antimicrobial peptides designed to target drug-resistant fungal ear infections.
-
AI-Designed Peptides: How RFpeptides Rewrote the First Step of Drug Discovery
RFpeptides, a deep-learning tool from David Baker's lab, designs macrocyclic peptide drugs from scratch. Here's how AI-designed peptides are changing discovery.
-
Amycretin and the Quiet Return of Amylin
Novo Nordisk's amycretin (zenagamtide) hits GLP-1 and amylin receptors in one peptide. Early trials show deep weight loss with no clear plateau. Full breakdown.
-
Designed Proteins Neutralize Snake Venom — and Hint at Antivenom Without the Horses
Lab-designed proteins neutralized lethal snake venom toxins in mice, pointing toward cheaper, heat-stable antivenom. Inside the Nature study and what it means.
-
GLP-1 and the Aging Brain: A Negative Result Worth Reading Twice
Semaglutide moved Alzheimer's biomarkers but failed to slow cognitive decline in the Evoke trials. What the negative result teaches about GLP-1 and the brain.
-
What the Liver Told Us: Semaglutide, MASH, and the ESSENCE Trial
The ESSENCE trial showed semaglutide reversed liver scarring in MASH on biopsy. Here's what the NEJM data mean for fatty liver disease treatment.
Frequently Asked Questions
What is the Peptide News Network's Research section?
The Research section of Peptide News Network is dedicated to covering new, peer-reviewed peptide science. According to the site, stories in this section cite primary sources and are written to translate peer-reviewed science for a general audience. As of the site's current state, the section is in its early launch phase, with content described as forthcoming.
Does Peptide News Network provide medical advice in its research coverage?
No. Peptide News Network explicitly states that nothing published on the site constitutes medical advice. The site encourages readers to consult a licensed clinician before making any health decisions. This disclaimer applies to all sections, including the Research section.
How does Peptide News Network ensure the accuracy of its research reporting?
According to the site, every story cites its primary sources. The publication describes its mission as reporting on peptide science, regulation, and industry based on peer-reviewed or authoritative material, and presenting that information in a way that is accessible to a general audience.
What topics does Peptide News Network cover beyond its Research section?
In addition to Research, Peptide News Network covers Clinical Trials, Regulation, Industry, and Explainers, as listed in its site navigation. The publication describes its overall focus as peptide science, regulation, and industry.
How can readers stay updated when new research articles are published on Peptide News Network?
Peptide News Network offers an RSS feed that readers can follow to be notified when new content is published. The site specifically notes that readers can 'follow the feed to catch the first one,' referring to upcoming research stories.
This content is for informational purposes only and is not medical advice. Consult a qualified healthcare professional for any medical concerns, diagnosis, or treatment.